|Trade names||Fluorodopa F18|
|Other names||6-fluoro-L-DOPA, FDOPA|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||214.18 g·mol-1|
|3D model (JSmol)|
The most common side effects are injection site pain.
Fluorodopa is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes (PS).
The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS. The trial was conducted at one clinical site in the United States.